Moreover, with the increasing prevalence of non-alcoholic fatty liver disease, AQP9 is gaining attention as a therapeutic target in HCC due to its function as a water and glycerol channel [37]. Here, AQP9 is linked to metabolic dysfunction-associated steatotic liver disease.